Affiliation:
1. Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA
Abstract
Although rarely curative, hepatic cytoreduction of neuroendocrine tumor liver metastases (NETLM) is associated with improved symptom control and prolonged survival. Preoperative 68Ga DOTATATE and gadoxetic acid-enhanced liver MRI can improve characterization of hepatic disease extent to improve surgical clearance, and resection of the primary tumor is associated with improved survival regardless of whether the liver metastases are treated. As parenchymal-sparing surgical techniques and the lowering of the debulking threshold have expanded the numbers of eligible NETLM patients for hepatic cytoreduction, we propose a new classification system to help guide surgical management. A multimodal approach that includes surgery, liver-directed therapies, and systemic therapies has improved outcomes and increased longevity for patients with well-differentiated metastatic NET.
Reference66 articles.
1. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes;Hallet;Cancer,2015
2. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J. Clin. Oncol.,2008
3. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms;Leoncini;Endocrine,2017
4. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?;Das;Curr. Oncol. Rep.,2021
5. Gastroenteropancreatic neuroendocrine tumors: Diagnosis and treatment;Salazar;Ann. Gastroenterol.,2013
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献